Cannabis Science and the Research Foundation Begins Protocols for California Legal Patients to Receive the New CBIS MDI Rescue Inhaler for Its First Observational Study Intending to Lead Into Clinical Trials

IRVINE, CA--(Marketwired - Aug 12, 2016) -  Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, is happy to announce the intent to seek out 20 - 25 potential candidates suffering from Asthma/COPD and other critical ailments. These initial patients will receive the New MDI Inhalation device FREE for monitoring usage habits, combination levels, and tracking medical results. The observational study is being designed to accumulate valuable data to lead into clinical trials in the State of California.

The CBIS MDI Rescue Inhaler dosage is targeting 100 - 200 dose MDI with cannabinoid level variations ranging from 10mg, 25mg, up to 100mg THC, CBD, and other cannabinoid variables as patient/consumer analysis moves further down the road.

"We are already receiving inquiries from patients looking to be a part of a cannabinoid study targeting several critical ailments so we are responding to the inherent demand from the consumers," stated CEO Mr. Raymond C. Dabney. "We believe we will get valuable feedback and clinical data from these participants that will aid us in establishing our products as an effective medication for these and other patients that suffer from so many different diseases. We are looking to have these patients in place by the time we launch and distribute this product to our partners and qualified legal vendors. We are very excited about this new product line and its potential to help these diminished lung function patients as well as the many other critical ailments we believe our cannabinoid formulations can help."

The Cannabis Science Research Foundation will be making the necessary changes to its website to receive the applications from interested patient/participants in this initial trial study. This trial study offer will be limited to the State of California and more specifically the city of Los Angeles.

"Many studies have been done and proven that the Cannabis compounds do indeed aid lung function and Cannabis Science is proud to be the one of the first to offer these types products to the people in the States where it is legal. We believe our new nebulizer medication as well as our CBIS MDI Rescue Inhaler will be a welcome addition to the arsenal of medications for Asthma/COPD suffers and the many other targeted ailments throughout the United States and worldwide," stated CEO Mr. Raymond C. Dabney.